MedPath

Feasibility Study of adjuvant chemotherapy of S-1/Oxaliplatin for patients with Stage III gastric cancer patients

Not Applicable
Recruiting
Conditions
Gastric cancer
Registration Number
JPRN-UMIN000023261
Lead Sponsor
Hamamatsu University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

1)Active synchronous metachronous malignancy with longer than 5year interval period without below written cases Carcinoma in situ of cervical cancer and focal cancer in adenoma of colorectal cancer. 2)Contraindication of S-1 and Oxaliplatin 3)Regular use of flucytosine, phenytoin or warfarin potassium 4)Active infection with over 38 degree fever 5)History of serious drug hypersensitivity 6)Any other serious illness or medical conditions including interstitial paresis, intestinal obstruction, pneumonitis, pulmonary fibrosis, uncontrolled diabetes, renal failure, liver failure. 7)HIV positive or active hepatitis 8)Severe diarrhea (over 4 times/day or watery diarrhea) 9)Pregnancy or lactation 10)Male intension that get with child 11) Patients who are recognized as inadequate patients by doctor with responsibility in this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Treatment completion rate of up to protocol treatment 5 courses.
Secondary Outcome Measures
NameTimeMethod
Adverse events occurrence rate
© Copyright 2025. All Rights Reserved by MedPath